Clovis Oncology, Inc.

Informe acción OTCPK:CLVS.Q

Capitalización de mercado: US$2.2m

Clovis Oncology Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Clovis Oncology has been growing earnings at an average annual rate of 5.6%, while the Biotechs industry saw earnings growing at 32.7% annually. Revenues have been growing at an average rate of 16.8% per year.

Información clave

5.6%

Tasa de crecimiento de los beneficios

24.5%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs 17.0%
Tasa de crecimiento de los ingresos16.8%
Rentabilidad financieran/a
Margen neto-189.4%
Última actualización de beneficios30 Sep 2022

Actualizaciones de resultados anteriores recientes

Recent updates

Clovis Oncology rises on clinical supply agreement with Isotopia

Sep 21

Clovis stock rises 15% as Rubraca shows survival benefit as maintenance therapy for ovarian cancer in trial

Sep 12

Clovis Oncology: Needs Some Encouraging Data Quickly

Aug 11

These Analysts Think Clovis Oncology, Inc.'s (NASDAQ:CLVS) Sales Are Under Threat

Aug 10
These Analysts Think Clovis Oncology, Inc.'s (NASDAQ:CLVS) Sales Are Under Threat

Clovis Oncology Q2 2022 Earnings Preview

Aug 05

EMA recommends restricted use of Clovis cancer drug

Jul 22

Clovis Oncology climbs 34% as shareholders reject reverse stock split

Jul 08

Clovis: Shifting Toward Nuclear Medicine

Apr 25

Clovis Oncology: Forging A Fresh Perspective

Mar 31

News Flash: 4 Analysts Think Clovis Oncology, Inc. (NASDAQ:CLVS) Earnings Are Under Threat

Feb 24
News Flash: 4 Analysts Think Clovis Oncology, Inc. (NASDAQ:CLVS) Earnings Are Under Threat

Buying Beaten Down Clovis Oncology Stock Ahead Of 2022 Catalysts

Jan 11

Clovis Oncology Is Now Discounted And Offers A Great Risk-Reward

Dec 30

Clovis Oncology Stock: Only Glimmers Of Hope

Oct 07

Clovis: Compelling With Upcoming Catalysts

Jul 30

Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet

Jun 17
Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet

Clovis Oncology and Inovio gain amid Reddit chatter

Jun 09

Clovis Oncology: Another Upcycle Coming

May 08

Clovis Oncology drops 7% as Rubraca sales missed estimates amid continued COVID-19 headwinds

May 05

Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)

Mar 17
Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)

How Much Did Clovis Oncology's(NASDAQ:CLVS) Shareholders Earn From Share Price Movements Over The Last Three Years?

Feb 22
How Much Did Clovis Oncology's(NASDAQ:CLVS) Shareholders Earn From Share Price Movements Over The Last Three Years?

Clovis Oncology: Recent Rally Already Has Me Changing My Game Plan

Jan 31

Clovis Oncology: Finally Green Shoots May Be On The Horizon

Jan 29

Clovis Oncology reports preliminary Q4 Rubraca revenue between $43.0M to $43.5M

Jan 11

What Kind Of Investors Own Most Of Clovis Oncology, Inc. (NASDAQ:CLVS)?

Dec 31
What Kind Of Investors Own Most Of Clovis Oncology, Inc. (NASDAQ:CLVS)?

Clovis Oncology submits FAP-2286 applications for therapeutic and imaging clinical trial

Dec 29

Clovis stock rises as rubraca shows survival benefit in late-stage ovarian cancer study

Dec 21

Clovis Oncology existing holder purchases additional $7.5M convertible senior notes

Nov 25

Clovis Oncology: Cash Position Is Tight, We Question Management's Guidance

Nov 09

Clovis Oncology: Reloading Before And After Q3 Earnings For The Long Term

Nov 06

Clovis Oncology EPS beats by $0.11, misses on revenue

Nov 05

Desglose de ingresos y gastos

Cómo gana y gasta dinero Clovis Oncology. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

OTCPK:CLVS.Q Ingresos, gastos y beneficios (USD Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
30 Sep 22133-252126151
30 Jun 22140-263127167
31 Mar 22145-258128176
31 Dec 21149-265128187
30 Sep 21156-299136201
30 Jun 21157-310142218
31 Mar 21160-336151242
31 Dec 20165-369164258
30 Sep 20161-370168273
30 Jun 20159-385171288
31 Mar 20152-413178289
31 Dec 19143-400183283
30 Sep 19134-400187282
30 Jun 19119-396187268
31 Mar 19110-377184250
31 Dec 1895-368176231
30 Sep 1882-321165198
30 Jun 1876-291158173
31 Mar 1867-366149154
31 Dec 1756-346139142
30 Sep 1739-365113159
30 Jun 1722-37087174
31 Mar 177-32460209
31 Dec 160-34941251
30 Sep 160-39837273
30 Jun 160-43136294
31 Mar 160-37334287
31 Dec 150-35331269
30 Sep 150-28828243
30 Jun 150-22925202
31 Mar 150-19223170
31 Dec 1414-16021138
30 Sep 1414-13419110
30 Jun 1414-1151891
31 Mar 1414-1001679
31 Dec 130-851767
30 Sep 130-761461
30 Jun 130-741260
31 Mar 130-711157
31 Dec 120-741158

Ingresos de calidad: CLVS.Q is currently unprofitable.

Margen de beneficios creciente: CLVS.Q is currently unprofitable.


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: CLVS.Q is unprofitable, but has reduced losses over the past 5 years at a rate of 5.6% per year.

Acelerando crecimiento: Unable to compare CLVS.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable

Beneficios vs. Industria: CLVS.Q is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-43.2%).


Rentabilidad financiera

Alta ROE: CLVS.Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado